Korea Research Institute of Chemical Technology (KRICT) and PINOTBIO have patented benzothiazole and benzimidazole derivatives acting as NAD-dependent protein deacetylase sirtuin-7 (SIRT7) inhibitors reported to be useful for the treatment of cancer, among other disorders.

PharminoGen has presented prazole-carboxamide derivatives acting as cannabinoid CB1 receptor antagonists reported to be useful for the treatment of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, dyslipidemia and diabetes.

Ascentage Pharma has discovered sulfonyl benzamide derivatives acting as apoptosis regulator Bcl-2 and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer.

The Consiglio Nazionale delle Ricerche and the Societa Industria Farmaceutica Italiana SpA (SIFI) have described new peptides acting as vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and VEGFR-2 inhibitors reported to be useful for the treatment of cancer, choroidal neovascularization, hematopoiesis disorders, macular edema, central retinal vein occlusion, central serous retinopathy, diabetic retinopathy and wet macular degeneration, among other disorders.

Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have divulged new morpholine derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists and reported to be useful for the treatment of cancer, pain, cough, depression, anxiety and genitourinary, gastrointestinal and immunological disorders, among other disorders.

Floratek has presented new chromen-4-one derivatives comprising a phosphonium quaternary group reported to be useful for the treatment of cancer.

Janssen and Johnson & Johnson have divulged dihydropyrimidine derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.

Medshine Discovery has patented pyrimidopyran-containing compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

China Hinye Pharmaceutical has presented new phenol derivatives acting as GABA(A) receptor alpha1beta2gamma2S positive allosteric modulators (PAMs) reported to be useful for the treatment of anxiety disorders, convulsions, migraine, nausea and vomiting and neurodegeneration.

XtalPi has discovered heterocyclic amide derivatives acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of pain, rheumatoid arthritis, osteoarthritis and cancer.